VistaGen Therapeutics(VTGN) - 2022 Q2 - Quarterly Report

Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-37761 VistaGen Therapeutics, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation ...